Our long-term objective is to cure cancer by combining conventional therapeutics that targeting on proliferative cells with novel therapy targeting dormant cancer cells. Currently, almost all anticancer drugs used in the clinic target proliferative cancer cells. While these effective anticancer treatments can lead to cancer dormancy – a state of cancer inactivity that is considered beneficial to the patient – it also renders them unresponsive to additional conventional treatments. As such, these dormant cancer cells can be considered the most resistant form of cancer. Unfortunately, they can eventually become reactivated in patients, causing cancer relapse and metastasis that kills. Our specific goal is to comprehensively understand the mechanisms understanding behind how dormant cancer cells relapse and progress into metastatic castration resistant prostate cancer (mCRPC). This will enable us to develop therapeutics that delay or prevent such occurrences. (Insights gained from studying prostate cancer can also be broadly applied to other cancer types given commonly shared mechanisms.)

Hypothesis: Therapy induces a heterogeneous, but definable, repertoire of mechanisms (e.g. lineage plasticity, transdifferentiation, and dormancy) that gives rise to lethal treatment-resistant CRPC. These mechanisms can be modeled and studied in patient-derived xenografts (PDXs), which are unique tools for discovering critical drug targets and testing novel anticancer therapies. By comprehensively understanding the mechanisms underlying cancer dormancy and reactivation, novel therapies can be developed.

Program significance: We anticipate that our research will build a new paradigm of cancer drug discovery and development by using evidence-based precision oncology and employing novel strategies that focus on eliminating dormant precursors of CRPC. Through our research program, we also hope to equip a next generation of scientists and clinical fellows to appreciate team science and interdisciplinary approaches. They will deepen their expertise in cancer modeling, molecular biology, and drug development. Using this combinatory approach, they will improve our understanding of the dynamic processes driving treatment resistance and develop the clinical tools necessary to impede cancer progression. Thus, our team’s synergy will significantly advance the knowledge of cancer biology and translate it to improving patient outcomes and quality of life.

Members

Faculty/Leaders

Staff

Post-Docs

Takashi Matsuoka

Post Doctoral Fellow

Students/Trainees

Adam Classen

PhD Student

Claire Marie Dourieu

Graduate Student

Zoe Maylin

PHD Student

Selected Publications

Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.

Gynecologic oncology, 2023
Wong, Nelson K Y, Llaurado Fernandez, Marta, Kommoss, Felix K F, Praveen Kumar, Pooja, Kim, Hannah, Liu, Jiahui, Zhang, Guihua, Coatham, Mackenzie, Lin, Yen-Yi, Haegert, Anne M, Volik, Stanislav, Le Bihan, Stephane, Collins, Colin C, Fu, Yangxin, Postovit, Lynne M, von Deimling, Andreas, Wu, Rebecca, Xue, Hui, Wang, Yuzhuo, Köbel, Martin, Carey, Mark S, Lee, Cheng-Han

Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.

Cancer research, 2023
Chou, Jonathan, Egusa, Emily A, Wang, Sinan, Badura, Michelle L, Lee, Fei, Bidkar, Anil P, Zhu, Jun, Shenoy, Tanushree, Trepka, Kai, Robinson, Troy M, Steri, Veronica, Huang, Jiaoti, Wang, Yuzhuo, Small, Eric J, Chan, Emily, Stohr, Bradley A, Ashworth, Alan, Delafontaine, Brant, Rottey, Sylvie, Cooke, Keegan S, Hashemi Sadraei, Nooshin, Yu, Brian, Salvati, Mark, Bailis, Julie M, Feng, Felix Y, Flavell, Robert R, Aggarwal, Rahul

The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms.

Molecular oncology, 2021
Mather, Rebecca L, Parolia, Abhijit, Carson, Sandra E, Venalainen, Erik, Roig-Carles, David, Jaber, Mustapha, Chu, Shih-Chun, Alborelli, Ilaria, Wu, Rebecca, Lin, Dong, Nabavi, Noushin, Jachetti, Elena, Colombo, Mario P, Xue, Hui, Pucci, Perla, Ci, Xinpei, Hawkes, Cheryl, Li, Yinglei, Pandha, Hardev, Ulitsky, Igor, Marconett, Crystal, Quagliata, Luca, Jiang, Wei, Romero, Ignacio, Wang, Yuzhuo, Crea, Francesco

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.

European urology, 2020
Herberts, Cameron, Murtha, Andrew J, Fu, Simon, Wang, Gang, Schönlau, Elena, Xue, Hui, Lin, Dong, Gleave, Anna, Yip, Steven, Angeles, Arkhjamil, Hotte, Sebastien, Tran, Ben, North, Scott, Taavitsainen, Sinja, Beja, Kevin, Vandekerkhove, Gillian, Ritch, Elie, Warner, Evan, Saad, Fred, Iqbal, Nayyer, Nykter, Matti, Gleave, Martin E, Wang, Yuzhuo, Annala, Matti, Chi, Kim N, Wyatt, Alexander W

Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.

EMBO reports, 2019
El-Naggar, Amal M, Somasekharan, Syam Prakash, Wang, Yemin, Cheng, Hongwei, Negri, Gian Luca, Pan, Melvin, Wang, Xue Qi, Delaidelli, Alberto, Rafn, Bo, Cran, Jordan, Zhang, Fan, Zhang, Haifeng, Colborne, Shane, Gleave, Martin, Mandinova, Anna, Kedersha, Nancy, Hughes, Christopher S, Surdez, Didier, Delattre, Olivier, Wang, Yuzhuo, Huntsman, David G, Morin, Gregg B, Sorensen, Poul H

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.

Science translational medicine, 2019
Puca, Loredana, Gavyert, Katie, Sailer, Verena, Conteduca, Vincenza, Dardenne, Etienne, Sigouros, Michael, Isse, Kumiko, Kearney, Megan, Vosoughi, Aram, Fernandez, Luisa, Pan, Heng, Motanagh, Samaneh, Hess, Judy, Donoghue, Adam J, Sboner, Andrea, Wang, Yuzhuo, Dittamore, Ryan, Rickman, David, Nanus, David M, Tagawa, Scott T, Elemento, Olivier, Mosquera, Juan Miguel, Saunders, Laura, Beltran, Himisha

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Genome medicine, 2019
Shrestha, Raunak, Nabavi, Noushin, Lin, Yen-Yi, Mo, Fan, Anderson, Shawn, Volik, Stanislav, Adomat, Hans H, Lin, Dong, Xue, Hui, Dong, Xin, Shukin, Robert, Bell, Robert H, McConeghy, Brian, Haegert, Anne, Brahmbhatt, Sonal, Li, Estelle, Oo, Htoo Zarni, Hurtado-Coll, Antonio, Fazli, Ladan, Zhou, Joshua, McConnell, Yarrow, McCart, Andrea, Lowy, Andrew, Morin, Gregg B, Chen, Tianhui, Daugaard, Mads, Sahinalp, S Cenk, Hach, Faraz, Le Bihan, Stephane, Gleave, Martin E, Wang, Yuzhuo, Churg, Andrew, Collins, Colin C

ONECUT2 is a driver of neuroendocrine prostate cancer.

Nature communications, 2019
Guo, Haiyang, Ci, Xinpei, Ahmed, Musaddeque, Hua, Junjie Tony, Soares, Fraser, Lin, Dong, Puca, Loredana, Vosoughi, Aram, Xue, Hui, Li, Estelle, Su, Peiran, Chen, Sujun, Nguyen, Tran, Liang, Yi, Zhang, Yuzhe, Xu, Xin, Xu, Jing, Sheahan, Anjali V, Ba-Alawi, Wail, Zhang, Si, Mahamud, Osman, Vellanki, Ravi N, Gleave, Martin, Bristow, Robert G, Haibe-Kains, Benjamin, Poirier, John T, Rudin, Charles M, Tsao, Ming-Sound, Wouters, Bradly G, Fazli, Ladan, Feng, Felix Y, Ellis, Leigh, van der Kwast, Theo, Berlin, Alejandro, Koritzinsky, Marianne, Boutros, Paul C, Zoubeidi, Amina, Beltran, Himisha, Wang, Yuzhuo, He, Housheng Hansen

Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019
Flores-Morales, Amilcar, Bergmann, Tobias B, Lavallee, Charlotte, Batth, Tanveer S, Lin, Dong, Lerdrup, Mads, Friis, Stine, Bartels, Anette, Kristensen, Gitte, Krzyzanowska, Agnieszka, Xue, Hui, Fazli, Ladan, Hansen, Klaus H, Røder, Martin A, Brasso, Klaus, Moreira, José M, Bjartell, Anders, Wang, Yuzhuo, Olsen, Jesper V, Collins, Colin C, Iglesias-Gato, Diego

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

The Prostate, 2018
Navone, Nora M, van Weerden, Wytske M, Vessella, Robert L, Williams, Elizabeth D, Wang, Yuzhuo, Isaacs, John T, Nguyen, Holly M, Culig, Zoran, van der Pluijm, Gabri, Rentsch, Cyril A, Marques, Rute B, de Ridder, Corrina M A, Bubendorf, Lukas, Thalmann, George N, Brennen, William Nathaniel, Santer, Frédéric R, Moser, Patrizia L, Shepherd, Peter, Efstathiou, Eleni, Xue, Hui, Lin, Dong, Buijs, Jeroen, Bosse, Tjalling, Collins, Anne, Maitland, Norman, Buzza, Mark, Kouspou, Michelle, Achtman, Ariel, Taylor, Renea A, Risbridger, Gail, Corey, Eva

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Molecular cancer therapeutics, 2018
Todenhöfer, Tilman, Seiler, Roland, Stewart, Craig, Moskalev, Igor, Gao, Jian, Ladhar, Simroop, Kamjabi, Alireza, Al Nakouzi, Nader, Hayashi, Tetsuharo, Choi, Stephen, Wang, Yuzhuo, Frees, Sebastian, Daugaard, Mads, Oo, Htoo Zarni, Fisel, Pascale, Schwab, Matthias, Schaeffeler, Elke, Douglas, James, Hennenlotter, Jörg, Bedke, Jens, Gibb, Ewan A, Fazli, Ladan, Stenzl, Arnulf, Black, Peter C

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

GigaScience, 2018
Ramnarine, Varune Rohan, Alshalalfa, Mohammed, Mo, Fan, Nabavi, Noushin, Erho, Nicholas, Takhar, Mandeep, Shukin, Robert, Brahmbhatt, Sonal, Gawronski, Alexander, Kobelev, Maxim, Nouri, Mannan, Lin, Dong, Tsai, Harrison, Lotan, Tamara L, Karnes, R Jefferey, Rubin, Mark A, Zoubeidi, Amina, Gleave, Martin E, Sahinalp, Cenk, Wyatt, Alexander W, Volik, Stanislav V, Beltran, Himisha, Davicioni, Elai, Wang, Yuzhuo, Collins, Colin C

Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

European urology, 2018
Mo, Fan, Lin, Dong, Takhar, Mandeep, Ramnarine, Varune Rohan, Dong, Xin, Bell, Robert H, Volik, Stanislav V, Wang, Kendric, Xue, Hui, Wang, Yuwei, Haegert, Anne, Anderson, Shawn, Brahmbhatt, Sonal, Erho, Nicholas, Wang, Xinya, Gout, Peter W, Morris, James, Karnes, R Jeffrey, Den, Robert B, Klein, Eric A, Schaeffer, Edward M, Ross, Ashley, Ren, Shancheng, Sahinalp, S Cenk, Li, Yingrui, Xu, Xun, Wang, Jun, Wang, Jian, Gleave, Martin E, Davicioni, Elai, Sun, Yinghao, Wang, Yuzhuo, Collins, Colin C

Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

Nature medicine, 2017
Zhang, Pingzhao, Wang, Dejie, Zhao, Yu, Ren, Shancheng, Gao, Kun, Ye, Zhenqing, Wang, Shangqian, Pan, Chun-Wu, Zhu, Yasheng, Yan, Yuqian, Yang, Yinhui, Wu, Di, He, Yundong, Zhang, Jun, Lu, Daru, Liu, Xiuping, Yu, Long, Zhao, Shimin, Li, Yao, Lin, Dong, Wang, Yuzhuo, Wang, Liguo, Chen, Yu, Sun, Yinghao, Wang, Chenji, Huang, Haojie

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.

Blood, 2016
Chapuy, Bjoern, Cheng, Hongwei, Watahiki, Akira, Ducar, Matthew D, Tan, Yuxiang, Chen, Linfeng, Roemer, Margaretha G M, Ouyang, Jing, Christie, Amanda L, Zhang, Liye, Gusenleitner, Daniel, Abo, Ryan P, Farinha, Pedro, von Bonin, Frederike, Thorner, Aaron R, Sun, Heather H, Gascoyne, Randy D, Pinkus, Geraldine S, van Hummelen, Paul, Wulf, Gerald G, Aster, Jon C, Weinstock, David M, Monti, Stefano, Rodig, Scott J, Wang, Yuzhuo, Shipp, Margaret A

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

Cell reports, 2015
Akamatsu, Shusuke, Wyatt, Alexander W, Lin, Dong, Lysakowski, Summer, Zhang, Fan, Kim, Soojin, Tse, Charan, Wang, Kendric, Mo, Fan, Haegert, Anne, Brahmbhatt, Sonal, Bell, Robert, Adomat, Hans, Kawai, Yoshihisa, Xue, Hui, Dong, Xin, Fazli, Ladan, Tsai, Harrison, Lotan, Tamara L, Kossai, Myriam, Mosquera, Juan Miguel, Rubin, Mark A, Beltran, Himisha, Zoubeidi, Amina, Wang, Yuzhuo, Gleave, Martin E, Collins, Colin C

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

JAMA oncology, 2015
Beltran, Himisha, Eng, Kenneth, Mosquera, Juan Miguel, Sigaras, Alexandros, Romanel, Alessandro, Rennert, Hanna, Kossai, Myriam, Pauli, Chantal, Faltas, Bishoy, Fontugne, Jacqueline, Park, Kyung, Banfelder, Jason, Prandi, Davide, Madhukar, Neel, Zhang, Tuo, Padilla, Jessica, Greco, Noah, McNary, Terra J, Herrscher, Erick, Wilkes, David, MacDonald, Theresa Y, Xue, Hui, Vacic, Vladimir, Emde, Anne-Katrin, Oschwald, Dayna, Tan, Adrian Y, Chen, Zhengming, Collins, Colin, Gleave, Martin E, Wang, Yuzhuo, Chakravarty, Dimple, Schiffman, Marc, Kim, Robert, Campagne, Fabien, Robinson, Brian D, Nanus, David M, Tagawa, Scott T, Xiang, Jenny Z, Smogorzewska, Agata, Demichelis, Francesca, Rickman, David S, Sboner, Andrea, Elemento, Olivier, Rubin, Mark A

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
Azad, Arun A, Volik, Stanislav V, Wyatt, Alexander W, Haegert, Anne, Le Bihan, Stephane, Bell, Robert H, Anderson, Shawn A, McConeghy, Brian, Shukin, Robert, Bazov, Jenny, Youngren, Jack, Paris, Pamela, Thomas, George, Small, Eric J, Wang, Yuzhuo, Gleave, Martin E, Collins, Colin C, Chi, Kim N

Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.

Cancer cell, 2015
El-Naggar, Amal M, Veinotte, Chansey J, Cheng, Hongwei, Grunewald, Thomas G P, Negri, Gian Luca, Somasekharan, Syam Prakash, Corkery, Dale P, Tirode, Franck, Mathers, Joan, Khan, Debjit, Kyle, Alastair H, Baker, Jennifer H, LePard, Nancy E, McKinney, Steven, Hajee, Shamil, Bosiljcic, Momir, Leprivier, Gabriel, Tognon, Cristina E, Minchinton, Andrew I, Bennewith, Kevin L, Delattre, Olivier, Wang, Yuzhuo, Dellaire, Graham, Berman, Jason N, Sorensen, Poul H

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
Yamamoto, Yoshiaki, Loriot, Yohann, Beraldi, Eliana, Zhang, Fan, Wyatt, Alexander W, Al Nakouzi, Nader, Mo, Fan, Zhou, Tianyuan, Kim, Youngsoo, Monia, Brett P, MacLeod, A Robert, Fazli, Ladan, Wang, Yuzhuo, Collins, Colin C, Zoubeidi, Amina, Gleave, Martin

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

Nature, 2015
Eirew, Peter, Steif, Adi, Khattra, Jaswinder, Ha, Gavin, Yap, Damian, Farahani, Hossein, Gelmon, Karen, Chia, Stephen, Mar, Colin, Wan, Adrian, Laks, Emma, Biele, Justina, Shumansky, Karey, Rosner, Jamie, McPherson, Andrew, Nielsen, Cydney, Roth, Andrew J L, Lefebvre, Calvin, Bashashati, Ali, de Souza, Camila, Siu, Celia, Aniba, Radhouane, Brimhall, Jazmine, Oloumi, Arusha, Osako, Tomo, Bruna, Alejandra, Sandoval, Jose L, Algara, Teresa, Greenwood, Wendy, Leung, Kaston, Cheng, Hongwei, Xue, Hui, Wang, Yuzhuo, Lin, Dong, Mungall, Andrew J, Moore, Richard, Zhao, Yongjun, Lorette, Julie, Nguyen, Long, Huntsman, David, Eaves, Connie J, Hansen, Carl, Marra, Marco A, Caldas, Carlos, Shah, Sohrab P, Aparicio, Samuel

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.

Genome biology, 2014
Wyatt, Alexander W, Mo, Fan, Wang, Kendric, McConeghy, Brian, Brahmbhatt, Sonal, Jong, Lina, Mitchell, Devon M, Johnston, Rebecca L, Haegert, Anne, Li, Estelle, Liew, Janet, Yeung, Jake, Shrestha, Raunak, Lapuk, Anna V, McPherson, Andrew, Shukin, Robert, Bell, Robert H, Anderson, Shawn, Bishop, Jennifer, Hurtado-Coll, Antonio, Xiao, Hong, Chinnaiyan, Arul M, Mehra, Rohit, Lin, Dong, Wang, Yuzhuo, Fazli, Ladan, Gleave, Martin E, Volik, Stanislav V, Collins, Colin C

High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.

Cancer research, 2014
Lin, Dong, Wyatt, Alexander W, Xue, Hui, Wang, Yuwei, Dong, Xin, Haegert, Anne, Wu, Rebecca, Brahmbhatt, Sonal, Mo, Fan, Jong, Lina, Bell, Robert H, Anderson, Shawn, Hurtado-Coll, Antonio, Fazli, Ladan, Sharma, Manju, Beltran, Himisha, Rubin, Mark, Cox, Michael, Gout, Peter W, Morris, James, Goldenberg, Larry, Volik, Stanislav V, Gleave, Martin E, Collins, Colin C, Wang, Yuzhuo

ERBB4 confers metastatic capacity in Ewing sarcoma.

EMBO molecular medicine, 2013
Mendoza-Naranjo, Ariadna, El-Naggar, Amal, Wai, Daniel H, Mistry, Priti, Lazic, Nikola, Ayala, Fernanda Rocha Rojas, da Cunha, Isabela Werneck, Rodriguez-Viciana, Pablo, Cheng, Hongwei, Tavares Guerreiro Fregnani, Jose H, Reynolds, Patrick, Arceci, Robert J, Nicholson, Andrew, Triche, Timothy J, Soares, Fernando A, Flanagan, Adrienne M, Wang, Yuzhuo Z, Strauss, Sandra J, Sorensen, Poul H

Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.

Molecular cancer therapeutics, 2012
Collins, Colin C, Volik, Stanislav V, Lapuk, Anna V, Wang, Yuwei, Gout, Peter W, Wu, Chunxiao, Xue, Hui, Cheng, Hongwei, Haegert, Anne, Bell, Robert H, Brahmbhatt, Sonal, Anderson, Shawn, Fazli, Ladan, Hurtado-Coll, Antonio, Rubin, Mark A, Demichelis, Francesca, Beltran, Himisha, Hirst, Martin, Marra, Marco, Maher, Christopher A, Chinnaiyan, Arul M, Gleave, Martin, Bertino, Joseph R, Lubin, Martin, Wang, Yuzhuo

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Cancer discovery, 2011
Beltran, Himisha, Rickman, David S, Park, Kyung, Chae, Sung Suk, Sboner, Andrea, MacDonald, Theresa Y, Wang, Yuwei, Sheikh, Karen L, Terry, Stéphane, Tagawa, Scott T, Dhir, Rajiv, Nelson, Joel B, de la Taille, Alexandre, Allory, Yves, Gerstein, Mark B, Perner, Sven, Pienta, Kenneth J, Chinnaiyan, Arul M, Wang, Yuzhuo, Collins, Colin C, Gleave, Martin E, Demichelis, Francesca, Nanus, David M, Rubin, Mark A

Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006
Cutz, Jean-Claude, Guan, Jun, Bayani, Jane, Yoshimoto, Maisa, Xue, Hui, Sutcliffe, Margaret, English, John, Flint, Julia, LeRiche, Jean, Yee, John, Squire, Jeremy A, Gout, Peter W, Lam, Stephen, Wang, Yu-Zhuo

Projects

Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer

Men with low to intermediate risk prostate cancer (PCa) face vexing decisions regarding treatment. The tumour can remain indolent and will not impact the patient within his lifetime, or it can progress to become life threatening (metastatic tumour). A holy grail of PCa research is the identification of prognostic biomarkers, which are biological factors that are associated with the disease outcomes, that can be used to improve patient risk stratification at time of diagnosis and guide treatment decisions.

Application of antibody internalization domain to improve the efficacy and safety of Antibody Drug Conjugates

Recent revolution in anti-cancer therapy utilizes the antibody's power to target cancer cells with chemotoxins. This approach of conjugating toxin to antibody (ADC= antibody drug conjugates) with specific affinity to cancer cells have dramatically improved both the safety and efficacy of the treatment. The most notable recent success is Kadcyla which combines DM1 toxin with anti-HER2 antibody to treat breast cancer. A critical factor in developing a successful ADC is an antibody's ability to internalize itself once it binds to the target cancer cell's biomarkers (receptors).

Identification of HP1a as a key regulator and a novel therapeutic target for neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is a currently incurable, lethal subtype of prostate cancer that can develop from the disease following prolonged hormonal therapy. Unfortunately, there are few treatment options available for NEPC and new therapeutic targets and more effective treatments are urgently needed to improve its management. A state-of-the-art pre-clinical model of NEPC, developed in our group, is giving us unprecedented levels of accuracy in monitoring how NEPC progresses.

Function and therapeutic potential of SUV420H2 in neuroendocrine prostate cancer

Treatment-resistant neuroendocrine prostate cancer (NEPC) is a currently incurable, lethal subtype of prostate cancer that usually develops following prolonged hormonal therapy. The only treatment option for NEPC is a highly toxic chemotherapy, which provides only limited survival benefits. Therefore, more effective treatments are urgently needed to improve the management of NEPC. Our current research goal is to understand how NEPC develops and progresses and pave the road to develop new therapy for the disease treatment.

Back to top